Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 14,800 shares, an increase of 5.7% from the October 31st total of 14,000 shares. Based on an average trading volume of 3,100 shares, the short-interest ratio is currently 4.8 days.
Intellipharmaceutics International Stock Performance
IPCIF opened at $0.08 on Friday. Intellipharmaceutics International has a 1-year low of $0.07 and a 1-year high of $0.30. The stock's fifty day simple moving average is $0.09 and its 200 day simple moving average is $0.09.
Get
Intellipharmaceutics International alerts:
About Intellipharmaceutics International
(Get Rating)
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Further Reading
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 14,800 shares, an increase of 5.7% from the October 31st total of 14,000 shares. Based on an average trading volume of 3,100 shares, the short-interest ratio is currently 4.8 days.
智能製藥國際公司(場外交易代碼：IPCIF-GET評級)(東京證券交易所代碼：I)是11月份空頭股數大幅上漲的目標。截至11月15日，空頭股數共有14,800股，比10月31日的14,000股增加了5.7%。以平均成交量3,100股計算，目前短息比率為4.8天。
Intellipharmaceutics International Stock Performance
IntelliPharmPharmtics International股票表現
IPCIF opened at $0.08 on Friday. Intellipharmaceutics International has a 1-year low of $0.07 and a 1-year high of $0.30. The stock's fifty day simple moving average is $0.09 and its 200 day simple moving average is $0.09.
IPCIF週五開盤報0.08美元。IntelliPharmPharmtics International的一年低點為0.07美元，一年高位為0.30美元。該股的50日簡單移動均線為0.09美元，200日簡單移動均線為0.09美元。
Get
Intellipharmaceutics International
alerts:
About Intellipharmaceutics International
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
IntelliPharmPharmtics International Inc.是一家制藥公司，在美國研究、開發和製造新型和仿製藥的控釋和靶向釋放口服固體劑量藥物。該公司在神經學、心血管、胃腸道、糖尿病和疼痛等不同治療領域基於其獲得專利的HyperMatrix技術開發各種藥物輸送系統、候選產品和一系列產品。
Further Reading
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免費獲取StockNews.com關於IntelliPharmPharmtics International(IPCIF)的研究報告
- 為什麼CSL有限公司的股票值得一看
- MarketBeat：回顧一週11/28-12/02
- Okta Inc.慶祝收益節節攀升，但他們能持續這種提振嗎？
- 機構正在購買安巴雷拉，你應該嗎？
- ZIM能否抵禦集裝箱航運業的普遍低迷？
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.
獲得IntelliPharmPharmtics International Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對IntelliPharmPharmtics International和相關公司的最新新聞和分析師評級的每日簡要摘要。
